AI Article Synopsis
- The study compares the effectiveness of colistin alone versus a combination of colistin and sulbactam for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in ICU patients.
- A total of 89 patients were assessed, with slightly better clinical response rates observed for the colistin/sulbactam group, especially at the end of treatment.
- While the combination therapy showed improved bacteriological response rates, the differences in overall clinical and microbiological outcomes between the two treatment groups were not statistically significant.
Article Abstract
Purpose: To compare clinical and microbiological efficacy of colistin and colistin/sulbactam for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii VAP in intensive care units (ICUs).
Patients And Methods: In this retrospective analysis, patients (>16 years-old) who received IV colistin or colistin/sulbactam for the treatment of MDR A. baumannii VAP were evaluated. The clinical and microbiological responses to therapies were assessed on the fifth day and at the end of the therapy.
Results: During the study period, 89 patients were enrolled into the study. Fifty-two (58.4 %) patients received colistin and 37 (41.6 %) patients received colistin/sulbactam therapy. The median APACHE II score was higher and diabetes mellitus was more common in the colistin/sulbactam group (p < 0.05). However, other demographic characteristics were not statistically significant between groups. On the fifth day of colistin and colistin/sulbactam therapies, clinical response rates were 40.4 and 43.2 %, respectively. At the end of the therapies, clinical response rates were 29.8 and 40 %, respectively. The bacteriological response rates were 72.3 and 85.7 % in colistin and colistin/sulbactam groups, respectively. There were no statistically significant differences in clinical cure rates or bacteriological clearance rates between the two groups.
Conclusions: The colistin/sulbactam combination therapy is promising in severe MDR A. baumannii VAP. Although, the difference was not statistically significant, clinical cure rates or bacteriological clearance rates were better in the combination group than colistin monotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s15010-013-0495-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcriptomic investigations of polymyxins and colistin/sulbactam combination against carbapenem-resistant .
Comput Struct Biotechnol J
December 2024
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Carbapenem-resistant (CRAB) is a Priority 1 (Critical) pathogen urgently requiring new antibiotics. Polymyxins are a last-line option against CRAB-associated infections. This transcriptomic study utilized a CRAB strain to investigate mechanisms of bacterial killing with polymyxin B, colistin, colistin B, and colistin/sulbactam combination therapy.
View Article and Find Full Text PDFNavigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.
Clin Infect Dis
May 2023
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Article Synopsis
- Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is a major concern in antibiotic resistance, lacking therapies that effectively lower mortality rates or improve outcomes.
- Current clinical practice often involves antibiotic combination therapy, but there's no clear consensus on the best combinations, with traditional options like colistin and sulbactam under scrutiny.
- The review suggests a personalized treatment approach that considers individual patient factors, emerging therapies, and local resistance patterns, recommending a sulbactam-based regimen optimized for dosing, with potential adjustments pending new drug approvals.
Evaluation of combination therapies with colistin in an experimental mouse pneumonia model induced by carbapenem-resistant Acinetobacter baumannii strain.
Fundam Clin Pharmacol
August 2023
Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Suleyman Demirel University, Isparta, Turkey.
The treatment options are limited in Acinetobacter baumannii infections. In this study, the effectiveness of colistin monotherapy and combinations of colistin with different antibiotics were investigated in an experimental pneumonia model induced by carbapenem-resistant A. baumannii strain.
View Article and Find Full Text PDFPrediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Clin Pharmacokinet
October 2022
Department of Statistics, State University of Maringá, Maringá, Paraná, Brazil.
Background: The combination of polymyxins, meropenem, and sulbactam demonstrated efficacy against multi-drug-resistant bacillus Acinetobacter baumannii. These three antibiotics are commonly used against major blood, skin, lung, and heart muscle infections.
Objective: The objective of this study was to predict drug disposition and extrapolate the efficacy in these tissues using a physiologically based pharmacokinetic modeling approach that linked drug exposures to their target pharmacodynamic indices associated with antimicrobial activities against A.
Evaluation of sulbactam and colistin/sulbactam efficacy against multiple resistant Acinetobacter baumannii blood isolates.
Indian J Med Microbiol
October 2022
Suleyman Demirel University, Faculty of Pharmacy, Pharmaceutical Microbiology, Isparta, Turkey. Electronic address:
Purpose: We aimed to compare the results of the BD Phoenix (TM) M50 ID/AST system and the gold standard broth microdilution method. We also evaluated the potential of a new therapeutic combination (colistin/sulbactam) for colistin resistance among Acinetobacter baumanni strains.
Methods: Growth in blood samples was detected with the BACTEC (BD Becton Dickinson, ABD) continuous monitoring blood culture system.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!